Brought to you by 
Genome editing company Editas Medicine closes $43mm Series A round
02 May 2014
Executive Summary
Flagship Ventures, Polaris Partners, and Third Rock Ventures led a $43mm Series A financing for genome editing start-up Editas Medicine Inc. Partners Innovation Fund also participated. A principal from Polaris will be Editas’ interim president and a Third Rock Partner partner will act as interim CSO. Representatives from Polaris, Third Rock, and Flagship joined Editas’ board.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Macromolecule
-
Drug Delivery
-
Biotechnology
- Gene Therapy, Cell Therapy
- Large Molecule
-
Drug Discovery Tools
- Genomics-Proteomics
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Genome editing company Editas Medicine closes $43mm Series A round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice